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Summary 
On August 18, 2014 Assistant to the President for Homeland Security and Counterterrorism Lisa Monaco and 
Assistant to the President for Science and Technology John Holdren issued a memorandum titled, “Enhancing 
Biosafety and Biosecurity in the United States,” which urged all United States Government departments and 
agencies that work with infectious agents to take immediate and long-term steps to enhance safety and security 
of research to minimize the potential for future incidents.  All United States Government departments and 
agencies that possess, use, or transfer human, animal, or plant infectious agents or toxins were urged to perform 
a Safety Stand-Down, to include an immediate sweep of their facilities to verify that all Biological Select Agents 
and Toxins in their possession were appropriately registered, stored, and disposed of in accordance with 
applicable regulations. 
In July 2014, the Centers for Disease Control and Prevention (CDC) initiated a careful and deliberate review of its 
biosafety and biosecurity protocols and implemented a series of measures to improve laboratory safety practices 
across the agency, including a comprehensive search of laboratory and associated spaces to identify Biological 
Select Agents and Toxins (BSAT) and ensure their proper registration, safe stewardship, and secure storage or 
disposal, among other measures.  These measures also fulfill the immediate and long-term steps called for in the 
August 18, 2014 memorandum. CDC released a fact sheet describing its activities undertaken as part of the 
“Safety Stand Down.” 
For a summary of the U.S. Government-wide Safety Stand-Down, click here: http://www.cdc.gov/about/lab-
safety.  
Process and Findings  
During CDC’s comprehensive search and the “Safety Stand-Down” period, CDC conducted a search of 
approximately 1,000 rooms of laboratory space at CDC facilities across the United States, which included 
inventory and documentation for over 8 million samples.  
CDC’s review found no instances in which select agents were stored in non-secured areas.  
CDC identified eight instances in which BSAT were stored securely and safely but were outside of areas registered 
for those particular agents.   In each instance, multiple vials of material were found, totaling 100 vials.  The 
individual vials each contained 0.5 milliliters or less of material (with the exception of one vial that contained 1 
milliliter).  These vials were found in two laboratories at CDC’s Roybal campus in Atlanta, Georgia, and at the CDC 
and ATSDR Specimen Packaging, Inventory, and Repository (CASPIR), CDC’s long-term specimen storage facility. 
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These reported instances reflect findings of select agents including:  
Entity Discovery 
Date 
Discovered Agent or Toxin Quantity 
(out of 
over 8 
million 
samples 
reviewed) 
Resolution 
of Sample 
Indication of 
human 
exposure prior 
to or during 
BSAT discovery 
CDC 9/17/2014 Clostridium botulinum 8 vials Destroyed No 
CDC 9/17/2014 Burkholderia pseudomallei 1 vial Transferred 
to registered 
laboratory 
No 
CDC 9/17/2014 Brucella abortus, B. 
melitensis & B. suis 
6 vials Destroyed No 
CDC 9/18/2014 Francisella tularensis 3 vials Destroyed No 
CDC 9/25/2014 Clostridium botulinum, 
Francisella tularensis, 
Bacillus anthracis, Yersinia, 
pestis, Burkholderia 
pseudomallei, B. mallei, 
Brucella abortus, B. 
melitensis & B. suis 
27 vials Transferred 
to registered 
laboratory 
No 
CDC 9/26/2014 Burkholderia pseudomallei, 
Clostridium botulinum, 
Brucella melitensis & B. 
suis 
14 vials Transferred 
to registered 
laboratory 
No 
CDC 9/30/2014 Bacillus anthracis, 
Burkholderia pseudomallei, 
Brucella abortus, and B. 
melitensis 
5 vials Transferred 
to registered 
laboratory 
No 
CDC 9/30/2014 Clostridium botulinum, 
Francisella tularensis, 
Bacillus anthracis, 
Burkholderia pseudomallei, 
B. mallei, Brucella abortus, 
B. melitensis & B. suis 
36 vials Transferred 
to registered 
laboratory 
No 
 
• Bacillus anthracis, the bacterium that causes anthrax; 
• Brucella species (B. abortus, B. melitensis, B. suis).  Brucella is the cause of brucellosis, which is typically 
transmitted to humans from infected animals; 
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• Burkholderia mallei, the bacterium that causes glanders, which is primarily a disease affecting horses, but 
can also rarely affect humans;  
• Burkholderia pseudomallei, a bacterium that infects humans and animals and causes the disease 
melioidosis; 
• Clostridium botulinum, a bacterium that can produce the neurotoxin botulinum; and 
• Francisella tularensis, the bacterium that causes tularemia in animals and humans. 
All of these agents have either been destroyed or transferred to the correct designated area. In no case was 
there an indication of human exposure, including staff or the general public, to any of these agents or toxins.   
 
Additional CDC Actions 
 
Plans for Sustained Inventory Monitoring 
Following the “Safety Stand-Down,” CDC has taken action to improve specimen management practices including: 
• Revising procedures to improve inventory management and plans to implement enhanced out-processing 
procedures for departing staff that will include accounting for samples put into storage during that person’s 
tenure, to ensure proper subsequent disposition of samples.   
 
• Implementing a new electronic inventory system for all diagnostic specimens, human and animal sera, and 
potentially pathogenic materials requiring BSL-2 or greater containment.   
 
Comprehensive Review of Current Biosafety and Biosecurity Protocols 
Also as part of the “Safety Stand-Down,” CDC is updating laboratory protocols and expanding training programs 
to advance best practices in biosafety and biosecurity. For example: 
 
• CDC ceased all transfers of biological materials from all biosafety level 3 (BSL-3) and 4 (BSL-4) laboratories at all 
CDC facilities until each laboratory individually documented its practices and received approval to resume 
transfers of biological materials.  
• CDC established an external workgroup to examine laboratory safety and security.  
Opportunities for Improving Research Safety and Local Oversight Systems 
• CDC hosted sessions with laboratory researchers and other staff to emphasize the importance of rigorously 
adhering to established practices for storing, handling, and working with infectious agents, toxins, and other 
biological derived materials. 
 
• CDC hosted a series of Laboratory Safety Engagement Sessions to provide a laboratory-specific forum to elicit 
suggestions and concerns from staff regarding laboratory safety.  
  
• CDC created an internal listserve and website for more frequent communication with the CDC laboratory 
community.  
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• CDC worked with the Federal Experts Security Advisory Panel (FESAP) and other departments and agencies to 
identify needs and gaps and make recommendations to optimize biosafety, biosecurity, oversight and inventory 
management and control for BSAT and identify changes to guidance or policy necessary to improve biosafety 
and biosecurity.   
Next Steps  
Moving forward, CDC will continue to work to institutionalize the recommendations that stem from the “Safety 
Stand-Down” findings.  For example: 
 
• CDC is establishing an Associate Director for Laboratory Science and Safety, reporting directly to the CDC 
Director, to provide agency-wide leadership and accountability for laboratory science, safety, and quality.   
 
• CDC is identifying best practices to standardize electronic inventory documentation and management systems 
in BSAT and non-BSAT laboratories 
 
• CDC is enhancing biosafety and biosecurity training for laboratory staff, management, and leadership.  
 
• CDC is clarifying policies regarding handling and disposition of remaining laboratory samples when researchers, 
staff members or trainees depart from positions that involve BSAT.  
 
• CDC is implementing mechanisms to designate responsible individuals to oversee samples stored in common 
storage areas, including for non-BSAT facilities.    
 
• CDC is participating in an interagency group, established by the National Science and Technology Council, to 
conduct a comprehensive review of the impact that the select agent regulations have had on science, 
technology, and national security.  
 
The recommendations from these reviews will continue to inform CDC’s future policy to advance biosafety and 
biosecurity. CDC is committed to advancing biosafety and biosecurity in the United States and around the world 
as an integral component of the Global Health Security Agenda (GHSA).  For the latest updates and information 
regarding laboratory safety, visit http://www.cdc.gov/about/lab-safety.    
 
 
